12:00 AM
 | 
Feb 11, 2013
 |  BC Week In Review  |  Company News  |  Other News

Protalix endocrine/metabolic news

Protalix engaged Citigroup to assist in exploring strategic alternatives, including product partnering and technology sharing. At Sept. 30, 2012, Protalix had $50.2 million in cash and a nine-month operating loss of $2 million.

Protalix's ...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >